Fu Yu Reverses Losses With $72k Net Profit in H1 2024
Fu Yu Reverses Losses With $72k Net Profit in H1 2024
Revenue from its supply chain management arm, Fu Yu Supply Chain Solutions (FYSCS) more than tripled to $72.0m from $18.6m due to higher demand amidst a global economic recovery.Revenue grew 78% to $126.7m.
营业收入增长了78%至12670万美元。
Fu Yu reported a net profit of $72,000 for H1 2024, rebounding from the $3.9m loss incurred a year ago.
富裕集团报告2024年上半年净利润为72,000美元，从一年前的390万美元亏损中反弹。
Revenue for the period grew 78.0% to $126.7m, boosted by stronger contributions from both the manufacturing and supply chain management segments.
该期营业收入增长78.0%，至12670万美元，由于制造业和供应链管理部门的贡献增强。
Revenue from its supply chain management arm, Fu Yu Supply Chain Solutions (FYSCS) more than tripled to $72.0m from $18.6m due to higher demand amidst a global economic recovery.
由于全球经济复苏带来的需求增加，富裕供应链解决方案（FYSCS）的营业收入猛增至7200万美元，是1860万美元的三倍多。
Meanwhile, gross profit from the manufacturing segment rose 12.9% to $7.0m from $6.2m a year ago.
与一年前的620万美元相比，制造业部门的毛利润从700万美元上升了12.9%。
In a bourse filing, the company said that its manufacturing business grew 4% to $54.8m in H1 2024, driven by higher sales from Singapore and Malaysia, partially offset by lower turnover in China.
在交易所提交的文件中，该公司表示，其制造业务在2024年上半年增长了4%，达到5480万美元，受新加坡和马来西亚销售增加驱动，部分抵消了中国业务的萎缩。
Revenue from Singapore and Malaysia rose 6.6% to $21.0m and 39.1% to $17.8m, respectively, whilst revenue from China fell 20.4% to $16.0m. In addition, the higher-margin biomedical segment contributed 3.0% to total revenue for H1 2024.
新加坡和马来西亚的营业收入分别增长了6.6%和39.1%，分别达到2100万美元和1780万美元，而来自中国的营业收入下降了20.4%，只有1600万美元。此外，高利润的生物医药部门为2024年上半年总营收做出了3.0%的贡献。
